Skip to main content

Advertisement

SpringerLink
Log in

Follicular lymphoma: Management options in the era of targeted therapy

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

For the vast majority of patients diagnosed with follicular lymphoma, the disease is never cured. As a result, it becomes a “chronic disease” that must be managed over many years. A wide array of management options exist, and it is difficult to claim that one strategy is better than another. It remains to be proven that a particular initial therapy or a particular sequence of therapies is superior, if one defines “superior” as affecting survival. It also remains to be proven that immediate treatment is superior to a “watch and wait” approach in patients with low tumor burden. However, newer targeted approaches to treatment are providing additional treatment options, and they generally have more favorable side-effect profiles than traditional cytotoxic therapies. The challenge is determining how to best incorporate such targeted therapies into traditional treatment. Additionally, determining the true impact of newer therapies is not entirely straightforward, as selection bias often confounds trial results in follicular lymphoma. A new follicular lymphoma prognostic index should aid in the interpretation of future clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. International Lymphoma Study Group: A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project [abstract]. Blood. 1997, 89:3909–3918.

    Google Scholar 

  2. Fisher RI, LeBlanc M, Press OW, et al.: New treatment options have changed the natural history of follicular lymphoma. Blood. 2004, 104:168.

    Google Scholar 

  3. Decaudin D, Lepage E, Brousse N, et al.: Low-grade stage III–IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients-a study of the groupe d’Etude des lymphomes de l’Adulte. J Clin Oncol 1999, 17:2499–2505.

    PubMed  CAS  Google Scholar 

  4. Coiffier B, Bastion Y, Berger F, et al.: Prognostic factors in follicular lymphomas. Semin Oncol, 1993, 20:89–95.

    PubMed  CAS  Google Scholar 

  5. Gallagher CJ, Gregory WM, Jones AE, et al.: Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 1986, 4:1470–1480.

    PubMed  CAS  Google Scholar 

  6. Federico M, Vitolo U, Zinzani PL, et al.: Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi Blood 2000, 95:783–789.

    CAS  Google Scholar 

  7. Foussard C, Desablens B, Sensebe L, et al.: Is the International Prognostic Index for aggressive lympho-mas useful for low-grade lymphoma patients? Applicability to stage III to IV patients. The GOELAMS Group, France. Ann Oncol 1997, 8(Suppl 1):49–52.

    Article  PubMed  Google Scholar 

  8. Hermans J, Krol AD, van Groningen K, et al.: International prognostic index for aggressive non-Hodgkin’s lymphoma is valid for all malignancy grades. Blood 1995, 86:1460–1463.

    PubMed  CAS  Google Scholar 

  9. Solal-Celigny P, Roy P, Colombat P, et al.: Follicular lymphoma international prognostic index. Blood 2004, 104:1258–1265. This manuscript outlines a validated prognostic system for follicular lymphoma. Understanding this index will help cli-nicians discuss prognosis with their newly diagnosed patients, and will aid in the interpretation of clinical trial results.

    Article  PubMed  CAS  Google Scholar 

  10. McLaughlin P, Grillo-Lopez AJ, Link BK, et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825–2833.

    PubMed  CAS  Google Scholar 

  11. Coiffer B, Ketterer N, Haioun C, et al.: A multicenter, randomized phase II study of rituximab at two dosages in patients with relapsed or refractory intermediate or high-grade NHL or in elderly patients in first-line therapy. Blood 1997, 90:510a.

    Google Scholar 

  12. Piro LD, White CA, Grillo-Lopez AJ, et al.: Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol 1999, 10:655–661.

    Article  PubMed  CAS  Google Scholar 

  13. Davis TA, White CA, Grillo-Lopez AJ, et al.: Single-agent monoclonal antibody efficacy in bulky non-Hodgkin’s lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999, 17:1851–1857.

    PubMed  CAS  Google Scholar 

  14. Davis TA, Grillo-Lopez AJ, White CA, et al.: Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000, 18:3135–3143.

    PubMed  CAS  Google Scholar 

  15. Colombat P, Salles G, Brousse N, et al.: Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001, 97:101–106. These data were updated at the 2004 American Society of Hematology Meeting and reveal that 28% of the original cohort remain in remission over 5 years after their single course of rituximab.

    Article  PubMed  CAS  Google Scholar 

  16. Witzig TE, Vukov AM, Habermann TM, et al.: Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin’s lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 2005, 23:1103–1108.

    Article  PubMed  CAS  Google Scholar 

  17. Berinstein NL, Grillo-Lopez AJ, White CA, et al.: Associa-tion of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol 1998, 9:995–1001.

    Article  PubMed  CAS  Google Scholar 

  18. Hainsworth JD, Litchy S, Burris HA III, et al.: Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin’s lymphoma. J Clin Oncol 2002, 20:4261–4267.

    Article  PubMed  CAS  Google Scholar 

  19. Ghielmini M, Schmitz SF, Cogliatti SB, et al.: Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004, 103:4416–4423.

    Article  PubMed  CAS  Google Scholar 

  20. Webster K, Cella D: Quality of life in patients with low-grade non-Hodgkin’s lymphoma. Oncology (Huntingt) 1998, 12:697–714; discussion 714, 717, 721.

    CAS  Google Scholar 

  21. Hainsworth JD, Litchy S, Shaffer DW, et al.: Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin’s lymphoma—a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005, 23:1088–1095. This trial demonstrates more work is needed to optimally define how to best dose single agent rituximab.

    Article  PubMed  CAS  Google Scholar 

  22. Gordan LN, Grow WB, Pusateri A, et al.: Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol 2005, 23:1096–1102.

    Article  PubMed  CAS  Google Scholar 

  23. Czuczman MS, Grillo-Lopez AJ, White CA, et al.: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999, 17:268–276.

    PubMed  CAS  Google Scholar 

  24. Czuczman MS, Weaver R, Alkuzweny B, et al.: Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004, 22:4711–4716.

    Article  PubMed  CAS  Google Scholar 

  25. Hiddemann W, Forstpointer R, Kneba M, et al.: The addition of rituximab to combination chemotherapy with CHOP has a long lasting impact on subsequent treatment in remission in follicular lymphoma but not in mantle cell lymphoma: results of two prospective randomized studies of the German Low-Grade Lymphoma Study Group (GLSG). Blood 2004, 104:50.

    Google Scholar 

  26. Marcus R, Imrie K, Belch A, et al.: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005, 105:1417–1423.

    Article  PubMed  CAS  Google Scholar 

  27. Hochster HS, Weller EA, Ryan T, et al.: Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). J Clin Oncol. 2004, 22:558.

    Google Scholar 

  28. McLaughlin P, Rodrigues M, Hagemeister F, et al.: Stage IV Indolent lymphoma: A randomized study of concurrent vs. sequential use of FND chemotherapy and rituximab monoclonal antibody therapy with interferon maintenance. J Clin Oncol 2003, 22:564.

    Google Scholar 

  29. Witzig TE, Gordon LI, Cabanillas F, et al.: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2002, 20:2453–2463.

    Article  PubMed  CAS  Google Scholar 

  30. Witzig TE, Flinn IW, Gordon LI, et al.: Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol 2002, 20:3262–3269.

    Article  PubMed  CAS  Google Scholar 

  31. Vose JM, Wahl RL, Saleh M, et al.: Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol 2000, 18:1316–1323.

    PubMed  CAS  Google Scholar 

  32. Kaminski MS, Estes J, Zasadny KR, et al.: Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin’s lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000, 96:1259–1266.

    PubMed  CAS  Google Scholar 

  33. Kaminski MS, Zelenetz AD, Press OW, et al.: Pivotal study of iodine I131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol 2001, 19:3918–3928.

    PubMed  CAS  Google Scholar 

  34. Davies AJ, Rohatiner AZ, Howell S, et al.: Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2004, 22:1469–1479.

    Article  PubMed  CAS  Google Scholar 

  35. Gordon LI, Molina A, Witzig T, et al.: Durable responses after ibritumomab tiuxetan radioimmuno-therapy for CD20+ B-cell lymphoma: long-term follow-up of a phase I/II study. Blood 2004, 12:4429–4431.

    Article  CAS  Google Scholar 

  36. Press OW, Unger JM, Braziel RM, et al.: A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood 2003, 102:1606–1612.

    Article  PubMed  CAS  Google Scholar 

  37. Kaminski MS, Tuck M, Estes J, et al.: 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005, 352:441–449. Very exciting approach to the treatment of follicular lymphoma. Over one half of the patients remain in remission after a single one-week course of radioimmunotherapy.

    Article  PubMed  CAS  Google Scholar 

  38. Gopal AK, Gooley TA, Maloney DG, et al.: High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood 2003, 102:2351–2357.

    Article  PubMed  CAS  Google Scholar 

  39. O’Connor O, Wright J, Moskowitz C, et al.: A multi-center experience with single agent bortezomib in non-Hodgkin’s lymphoma reveals marked differences in subtype sensitivity to proteasome inhibition. Blood 2004, 204:174.

    Google Scholar 

  40. Goy A, Younes A, McLaughlin P, et al.: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2005, 23:667–675.

    Article  PubMed  CAS  Google Scholar 

  41. Hsu FJ, Caspar CB, Czerwinski D, et al.: Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma—long-term results of a clinical trial. Blood 1997, 89:3129–3135.

    PubMed  CAS  Google Scholar 

  42. Timmerman JM, Czerwinski DK, Davis TA, et al.: Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002, 99:1517–1526.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, University of Wisconsin, H4/534 CSC, 53792, Madison, WI, USA

    Brad S. Kahl MD

Authors
  1. Christopher G. Peterson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brad S. Kahl MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Peterson, C.G., Kahl, B.S. Follicular lymphoma: Management options in the era of targeted therapy. Curr. Treat. Options in Oncol. 6, 297–308 (2005). https://doi.org/10.1007/s11864-005-0034-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-005-0034-x

Keywords

Search

Navigation